Thiotepa, Etoposide, Cyclophosphamide, ARA-C and Melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma
High dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Conditioning regimens with high dose BCNU are associated with Idiopathic Pneumonitis Syndrome (IPS). We therefore created a modified alternative TECAM conditioning regimen, consisting of etoposide, thiotepa, cytarabine, cyclophosphamide and melphalan. We retrospectively analyzed our cohort of NHL and HL patients, who underwent ASCT with the TECAM conditioning between 2000 and 2013.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Sigal Grisariu, Michael Y. Shapira, Reuven Or, Batia Avni Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants